Department of Pediatrics, University of California San Diego, La Jolla, California.
Department of Medicine, University of California San Diego, La Jolla, California.
Semin Liver Dis. 2021 Jan;41(1):87-102. doi: 10.1055/s-0040-1719174. Epub 2021 Jan 14.
Alcohol-associated liver disease (ALD) and nonalcoholic fatty liver disease (NAFLD) are important causes of morbidity and mortality worldwide. The intestinal microbiota is involved in the development and progression of both ALD and NAFLD. Here we describe associated changes in the intestinal microbiota, and we detail randomized clinical trials in ALD and NAFLD which evaluate treatments modulating the intestinal microbiome including fecal microbiota transplantation, probiotics, prebiotics, synbiotics, and antibiotics. Finally, we discuss precision medicine approaches targeting the intestinal microbiome to ameliorate ALD and NAFLD.
酒精性肝病 (ALD) 和非酒精性脂肪性肝病 (NAFLD) 是全球发病率和死亡率的重要原因。肠道微生物群参与了 ALD 和 NAFLD 的发展和进展。在这里，我们描述了肠道微生物群的相关变化，并详细介绍了评估调节肠道微生物组的治疗方法的随机临床试验，包括粪便微生物群移植、益生菌、益生元、合生菌和抗生素。最后，我们讨论了针对肠道微生物组的精准医学方法，以改善 ALD 和 NAFLD。
